pairingsPairing
Durvalumab + BCG in BCG-naive high-risk NMIBC
Systemic immunotherapy layered on top of bladder BCG reduced recurrence, at the cost of systemic side effects in a disease usually treated locally.
POTOMAC DFS HR 0.68; approved May 2026. ALBAN (atezolizumab + BCG) was negative, so the effect is not automatically a class effect; CREST (sasanlimab + BCG) was positive.
Rationale
BCG primes a local Th1 response; PD-L1 blockade prevents its exhaustion and may reach micrometastatic disease.
Evidence
One positive phase 3 (POTOMAC), one negative (ALBAN), one positive with a different agent (CREST).
Pages like this
not linked directly; found by shared links- TermNon-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)
Shares POTOMAC, Intravesical BCG, Bladder & urothelial cancer.
- TrialQUILT 3.032
- IdeaTrain the bone marrow to make better anti-tumour immune cells
- TrialNIAGARA
Shares Durvalumab, Bladder & urothelial cancer.
- TermBCG-unresponsive
- Key paperNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer
Shares Durvalumab, Bladder & urothelial cancer.
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)